Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium (177Lu) oxodotreotide
- Development stage
- Approved
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lutetium (177Lu) oxodotreotide, marketed under the brand name Lutathera, is a radiopharmaceutical used in peptide receptor radionuclide therapy (PRRT). It consists of the beta-emitting radioisotope lutetium-177 chelated to dotatate (oxodotreotide), a somatostatin analog. The drug targets the somatostatin receptor subtype 2 (SSTR2), which is highly expressed on the surface of neuroendocrine tumor cells. Upon binding to SSTR2, the drug is internalized into the cell, where the emission of beta radiation from lutetium-177 causes localized DNA damage and subsequent cell death. It was developed by Advanced Accelerator Applications (AAA), a Novartis company, and is primarily indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The SEPTRALU study, sponsored by the Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM), is a significant retrospective observational study evaluating the efficacy and safety of this therapy in routine clinical practice within Spain.
- Brand names
- Lutathera
- Other names
- lutetium Lu 177 dotatateoxodotreotide177Lu-oxodotreotidelutetium (177Lu) dotatate
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lutetium (177Lu) oxodotreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium (177Lu) oxodotreotide.